Literature DB >> 9120427

Neuronal vulnerability in Parkinson's disease.

E C Hirsch1, B Faucheux, P Damier, A Mouatt-Prigent, Y Agid.   

Abstract

Although Parkinson's disease is characterized by a loss of dopaminergic neurons in the substantia nigra not all dopaminergic neurons degenerate in this disease. This suggests that some specific factors make subpopulations of dopaminergic neurons more susceptible to the disease. Here, we show that the most vulnerable neurons are particularly sensitive to oxidative stress and rise in intracellular calcium concentrations. Because both events seem to occur in Parkinson's disease this may explain why some dopaminergic neurons degenerate and other do not.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9120427     DOI: 10.1007/978-3-7091-6842-4_9

Source DB:  PubMed          Journal:  J Neural Transm Suppl        ISSN: 0303-6995


  30 in total

Review 1.  The role of iron in neurodegeneration: prospects for pharmacotherapy of Parkinson's disease.

Authors:  K A Jellinger
Journal:  Drugs Aging       Date:  1999-02       Impact factor: 3.923

Review 2.  Neuroinflammatory mechanisms in Parkinson's disease: potential environmental triggers, pathways, and targets for early therapeutic intervention.

Authors:  Malú G Tansey; Melissa K McCoy; Tamy C Frank-Cannon
Journal:  Exp Neurol       Date:  2007-07-17       Impact factor: 5.330

3.  Mitochondrial ATP-sensitive potassium channels enhance angiotensin-induced oxidative damage and dopaminergic neuron degeneration. Relevance for aging-associated susceptibility to Parkinson's disease.

Authors:  Jannette Rodriguez-Pallares; Juan Andres Parga; Belen Joglar; Maria Jose Guerra; Jose Luis Labandeira-Garcia
Journal:  Age (Dordr)       Date:  2011-06-29

4.  Transgenic mice expressing human Bcl-2 in their neurons are resistant to 6-hydroxydopamine and 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine neurotoxicity.

Authors:  D Offen; P M Beart; N S Cheung; C J Pascoe; A Hochman; S Gorodin; E Melamed; R Bernard; O Bernard
Journal:  Proc Natl Acad Sci U S A       Date:  1998-05-12       Impact factor: 11.205

5.  Exosomes-associated neurodegeneration and progression of Parkinson's disease.

Authors:  Isabella Russo; Luigi Bubacco; Elisa Greggio
Journal:  Am J Neurodegener Dis       Date:  2012-11-18

Review 6.  Mesencephalic and extramesencephalic dopaminergic systems in Parkinson's disease.

Authors:  Fanni F Geibl; Martin T Henrich; Wolfgang H Oertel
Journal:  J Neural Transm (Vienna)       Date:  2019-01-14       Impact factor: 3.575

7.  Tissue transglutaminase-induced aggregation of alpha-synuclein: Implications for Lewy body formation in Parkinson's disease and dementia with Lewy bodies.

Authors:  Eunsung Junn; Ruben D Ronchetti; Martha M Quezado; Soo-Youl Kim; M Maral Mouradian
Journal:  Proc Natl Acad Sci U S A       Date:  2003-02-07       Impact factor: 11.205

8.  Androgens induce dopaminergic neurotoxicity via caspase-3-dependent activation of protein kinase Cdelta.

Authors:  Rebecca L Cunningham; Andrea Giuffrida; James L Roberts
Journal:  Endocrinology       Date:  2009-10-16       Impact factor: 4.736

9.  Parkin-mediated ubiquitination regulates phospholipase C-gamma1.

Authors:  Nodi Dehvari; Anna Sandebring; Amilcar Flores-Morales; Laura Mateos; Yin-Choy Chuan; Matthew S Goldberg; Mark R Cookson; Richard F Cowburn; Angel Cedazo-Mínguez
Journal:  J Cell Mol Med       Date:  2008-07-30       Impact factor: 5.310

10.  The mitochondrial ATP-sensitive potassium channel blocker 5-hydroxydecanoate inhibits toxicity of 6-hydroxydopamine on dopaminergic neurons.

Authors:  J Rodriguez-Pallares; J A Parga; B Joglar; M J Guerra; J L Labandeira-Garcia
Journal:  Neurotox Res       Date:  2009-02-24       Impact factor: 3.911

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.